PARP inhibitors for BRCA1/2-mutated and sporadic ovarian cancer: current practice and future directions

por Konecny, G E, Kristeleit, R S
Publicado 2016

Glomerular filtration rate estimation for carboplatin dosing in patients with gynaecological cancers

por Samani, A., Bennett, R., Eremeishvili, K., Kalofonou, F., Whear, S., Montes, A., Kristeleit, R., Krell, J., McNeish, I., Ghosh, S., Tookman, L.
Publicado 2022

Prediction of early death among patients enrolled in phase I trials: development and validation of a new model based on platelet count and albumin

por Ploquin, A, Olmos, D, Lacombe, D, A'Hern, R, Duhamel, A, Twelves, C, Marsoni, S, Morales-Barrera, R, Soria, J-C, Verweij, J, Voest, E E, Schöffski, P, Schellens, J H, Kramar, A, Kristeleit, R S, Arkenau, H-T, Kaye, S B, Penel, N
Publicado 2012

1608P The impact of COVID-19 on the delivery of systemic anti-cancer treatment at Guy’s Cancer Centre

por Dolly, S., Russell, B., Moss, C.L., Tsotra, E., Gousis, C., Roca, J., Sita-Lumsden, A., Khan, M., Josephs, D., Zaki, K., Smith, D., Michalarea, V., Kristeleit, R., Enting, D., Flanders, L., Lei, M., Sawyer, E., Spicer, J., Ross, P., Montes, A., Van Hemelrijick, M.
Publicado 2021